For research use only. Not for therapeutic Use.
Zasocitinib（Cat No.:I042868）is an investigational oral Janus kinase (JAK) inhibitor being studied for the treatment of various autoimmune diseases, including rheumatoid arthritis and inflammatory conditions. By targeting specific JAK enzymes, it aims to disrupt inflammatory signaling pathways, reducing immune system activity that causes tissue damage. Zasocitinib offers a promising alternative to traditional therapies, potentially providing faster symptom relief with a more targeted mechanism. Its ongoing clinical trials focus on assessing its efficacy, safety, and long-term benefits in managing chronic inflammatory disorders and improving quality of life for patients.
| CAS Number | 2272904-53-5 |
| Synonyms | N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-[(2-oxo-1-pyridin-2-ylpyridin-3-yl)amino]pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| Molecular Formula | C23H24N8O3 |
| Purity | ≥95% |
| IUPAC Name | N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-[(2-oxo-1-pyridin-2-ylpyridin-3-yl)amino]pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| InChI | InChI=1S/C23H24N8O3/c1-24-20-12-18(27-16-6-5-11-30(23(16)33)19-7-3-4-10-25-19)29-21-14(13-26-31(20)21)22(32)28-15-8-9-17(15)34-2/h3-7,10-13,15,17,24H,8-9H2,1-2H3,(H,27,29)(H,28,32)/t15-,17-/m1/s1 |
| InChIKey | BWINBHTTZLVXGT-NVXWUHKLSA-N |
| SMILES | CNC1=CC(=NC2=C(C=NN12)C(=O)N[C@@H]3CC[C@H]3OC)NC4=CC=CN(C4=O)C5=CC=CC=N5 |
